open access

Vol 23, No 5 (2018)
Reviews
Published online: 2018-09-01
Submitted: 2017-12-12
Get Citation

Physical, dosimetric and clinical aspects and delivery systems in neutron capture therapy

Bagher Farhood, Hadi Samadian, Mahdi Ghorbani, Seyed Salman Zakariaee, Courtney Knaup
DOI: 10.1016/j.rpor.2018.07.002
·
Rep Pract Oncol Radiother 2018;23(5):462-473.

open access

Vol 23, No 5 (2018)
Reviews
Published online: 2018-09-01
Submitted: 2017-12-12

Abstract

Neutron capture therapy (NCT) is a targeted radiotherapy for cancer treatment. In this method, neutrons with a spectra/specific energy (depending on the type of agent used for NCT) are captured with an agent that has a high cross-section with these neutrons. There are some agents that have been proposed in NCT including 10B, 157Gd and 33S. Among these agents, only 10B is used in clinical trials. Application of 157Gd is limited to in-vivo and in-vitro research. In addition, 33S has been applied in the field of Monte Carlo simulation. In BNCT, the only two delivery agents which are presently applied in clinical trials are BPA and BSH, but other delivery systems are being developed for more effective treatment in NCT. Neutron sources used in NCT are fission reactors, accelerators, and 252Cf. Among these, fission reactors have the most application in NCT. So far, BNCT has been applied to treat various cancers including glioblastoma multiforme, malignant glioma, malignant meningioma, liver, head and neck, lung, colon, melanoma, thyroid, hepatic, gastrointestinal cancer, and extra-mammary Paget's disease. This paper aims to review physical, dosimetric and clinical aspects as well as delivery systems in NCT for various agents.

Abstract

Neutron capture therapy (NCT) is a targeted radiotherapy for cancer treatment. In this method, neutrons with a spectra/specific energy (depending on the type of agent used for NCT) are captured with an agent that has a high cross-section with these neutrons. There are some agents that have been proposed in NCT including 10B, 157Gd and 33S. Among these agents, only 10B is used in clinical trials. Application of 157Gd is limited to in-vivo and in-vitro research. In addition, 33S has been applied in the field of Monte Carlo simulation. In BNCT, the only two delivery agents which are presently applied in clinical trials are BPA and BSH, but other delivery systems are being developed for more effective treatment in NCT. Neutron sources used in NCT are fission reactors, accelerators, and 252Cf. Among these, fission reactors have the most application in NCT. So far, BNCT has been applied to treat various cancers including glioblastoma multiforme, malignant glioma, malignant meningioma, liver, head and neck, lung, colon, melanoma, thyroid, hepatic, gastrointestinal cancer, and extra-mammary Paget's disease. This paper aims to review physical, dosimetric and clinical aspects as well as delivery systems in NCT for various agents.

Get Citation

Keywords

NCT; BNCT; GdNCT; SNCT; Delivery system252Cf

About this article
Title

Physical, dosimetric and clinical aspects and delivery systems in neutron capture therapy

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 23, No 5 (2018)

Pages

462-473

Published online

2018-09-01

DOI

10.1016/j.rpor.2018.07.002

Bibliographic record

Rep Pract Oncol Radiother 2018;23(5):462-473.

Keywords

NCT
BNCT
GdNCT
SNCT
Delivery system252Cf

Authors

Bagher Farhood
Hadi Samadian
Mahdi Ghorbani
Seyed Salman Zakariaee
Courtney Knaup

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl